文献速递淋巴瘤

80岁及以上慢性淋巴细胞白血病患者治疗结局分析

Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia.
PubMed 文献 · Br J Haematol · 2018-11-21

基于德国慢性淋巴细胞白血病研究组七项III期临床试验数据,3552例参与者中152例在启动一线研究治疗时年龄≥80岁,中位年龄82岁,99%存在伴随疾病。中位无进展生存期17.2个月,中位总生存期48.3个月,3/4级中性粒细胞减少和感染发生率分别为35%和13%。作者认为含化学免疫治疗在内的抗白血病治疗在该人群可行且有效。

要点

  • ≥80岁慢性淋巴细胞白血病患者一线治疗中位无进展生存期17.2个月、中位总生存期48.3个月。
  • 3/4级中性粒细胞减少发生率35%,3/4级感染发生率13%。
  • 总缓解率77%,完全缓解率13%。

核心结论

  • 作者认为,包括化学免疫治疗在内的抗白血病治疗在≥80岁慢性淋巴细胞白血病患者中可行且有效。
  • 但该组患者生存时间短于一般人群中年龄匹配的对照。

研究设计与样本

  • 利用德国慢性淋巴细胞白血病研究组七项III期临床试验的数据进行分析。
  • 3552例参与者中,152例在启动一线研究治疗时年龄≥80岁。
  • 中位年龄82岁(范围80-90)。

主要发现

  • 99%的患者存在伴随疾病,累积疾病评定量表中位评分为8分(0-18)。
  • 61例(40%)接受苯丁酸氮芥-奥妥珠单抗(CLB-OB)治疗,56例(37%)接受苯丁酸氮芥-利妥昔单抗(CLB-R)治疗。
  • 其余患者分别接受苯丁酸氮芥(n=19)、氟达拉滨(F,n=10)、F/环磷酰胺(FC,n=1)、FC/利妥昔单抗(FCR,n=2)或苯达莫司汀/利妥昔单抗(BR,n=3)治疗。
  • 3/4级中性粒细胞减少发生率为35%,3/4级感染发生率为13%。
  • 总缓解率为77%,完全缓解率为13%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical management of chronic lymphocytic leukaemia (CLL) in patients aged ≥80 years is based on limited evidence due to the lack of published information. Therefore, we analysed CLL patients aged ≥80 years using data from seven phase III clinical trials of the German CLL Study Group. Among 3552 participants, 152 were ≥80 years old at initiation of first-line study treatment. Median age was 82 years (range 80-90). Concomitant diseases were present in 99% of the patients, with a median cumulative illness rating scale score of 8 (0-18). Chemoimmunotherapy with chlorambucil-obinutuzumab (CLB-OB) or chlorambucil-rituximab (CLB-R) was administered to 61 (40%) and 56 (37%) patients. The remaining patients received CLB (n = 19) or fludarabine (F, n = 10), F/cyclophosphamide (FC, n = 1), FC/rituximab (FCR, n = 2) or bendamustine/rituximab (BR, n = 3). Rates of grade 3 or 4 neutropenia and infections were 35% and 13%. Overall response rate was 77% with 13% complete remissions. Median progression-free survival and treatment-free survival were 17·2 and 32·3 months, respectively. Median overall survival was 48·3 months; adverse events (22%) and progressive CLL (16·4%) were the most frequent causes of death. These findings suggest that anti-leukaemic treatment including chemoimmunotherapy is feasible and efficacious in ≥80-year-old CLL patients. However, this group of patients lives for a shorter time than age-matched controls of the general population.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Al-Sawaf O, Bahlo J, Robrecht S, et al. Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia. Br J Haematol. 2018. PMID: 30460980. doi:10.1111/bjh.15604

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。